ABSTRACT
Colonic T cell/histiocyte rich large B cell lymphoma (THRLBCL) is a very unusual occurrence never described before. A 41-year anaemic male presented with loss of weight and appetite for 7 months and fever with Malena for 1 month. Abdominal examination revealed a 4×6 cm retroperitoneal lump in the right iliac fossa. Radiological investigations (USG and CECT whole abdomen) reported an asymmetrical ill-defined growth in ascending colon and caecum with loco-regional lymphadenopathy. Surgical exploration revealed an ascending colon mass with retroperitoneal lymphadenopathy. Right hemi-colectomy with end ileostomy was done and specimen was sent for histopathology which diagnosed it to be a case of THRLBCL of colon. Patient was followed up after 2 weeks and was planned for chemotherapy.
ABSTRACT
Purpose To investigate the expression and clinical significance of p63 in nodular lymphocyte predominant Hodgkin lym-phoma (NLPHL) and classical Hodgkin lymphoma (CHL). Methods 15 cases of NLPHL and 54 cases of CHL were stained for CD45, CD30, p63, PAX5, CD20, CD15, Oct-2, BOB1, MUM1, EMA, EBV-LMP1 and Ki-67 by immunohistochemical methods of EliVision. EBER were detected by in situ hybridization method in 12 cases of CHL. Results The expression of p63 in NLPHL (53. 3%, 8/15) was significantly higher than that in CHL (0, 0/54) (P<0. 05). Conclusions p63 protein is frequently expressed in NLPHL and helpful in the differential diagnosis between NLPHL and CHL.
ABSTRACT
A variety of lymphoma types have been reported in patients being treated with anticonvulsant therapy. Non-Hodgkin lymphomas have been reported twice as frequently as Hodgkin lymphomas. Association of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) with dilantin therapy is extremely uncommon. We report a case of Hodgkin lymphoma in a 25-year-old male patient who had been treated with diphenylhydantoin sodium for generalized tonic clonic seizures for 15 years. Patient presented with left cervical and axillary lymphadenopathy persisting for more than 2 years after cessation of treatment with diphenylhydantoin. Computerized tomography scan of thorax, abdomen and pelvis revealed no signifi cant lymphadenopathy or any organomegaly. Diagnosis of NLPHL was made on excision biopsy of the cervical lymph node. Although the association between diphenylhydantoin therapy and the development of immunosuppression and lymphoma is well-documented, the role of the drug in the etiology of these disorders is still controversial.
ABSTRACT
Recent advances in the understanding of the biology of Hodgkin lymphoma have led to a new classification. Hodgkin lymphoma is now recognized as a B-cell disorder of germinal center or post-germinal center origin. In the WHO classification, Hodgkin lymphoma consists of two categories, namely, nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Classical Hodgkin lymphoma encompasses not only nodular sclerosis, mixed cellularity, and lymphocyte depletion subtypes, but also lymphocyte-rich subtype, among which, nodular sclerosis stands out as a distinct entity. A borderline neoplasm with features intermediate between Hodgkin lymphoma and diffuse large B-cell lymphoma has also been recognized.
Subject(s)
B-Lymphocytes , Biology , Diagnosis, Differential , Germinal Center , Hodgkin Disease , Lymphocyte Depletion , Lymphocytes , Lymphoma, B-Cell , SclerosisABSTRACT
Objective To investigate the clinicopathological characteristics and treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Methods Seven patients were confirmed as NLPHL by pathologic immunohistochemistry. Six patients received combined-modality therapy of chemotherapy and involved field, and the other one received single chemotherapy. Results The 3-year local control rate and overall survival rate were 100 % and 86 %, respectively. Only one case died of pulmonary infection following chemotherapy. Conclusion These patients with NLPHL has favorable prognosis, tolerance and less toxicity for combined-modality therapy. However the management of toxicity following treatment should be noted.